Related by context. All words. (Click for frequent words.) 81 Patent Broadly Covering 80 Patents Covering 80 Drug Candidate 80 Patent Issued 79 Receives Orphan Drug Designation 78 Files IND 78 Completes Patient Enrollment 77 Presents Preclinical Data 77 Clinical Trial Results 77 Receives Patent 76 Exclusive License 76 Meets Primary Endpoint 76 Completes Enrollment 76 Receives Milestone Payment 75 Systemic Delivery 75 Fast Track Status 75 FDA Clearance 75 Small Molecule 75 Initiates Clinical Trial 75 FDA Clears 75 Receives Orphan Drug 75 Present Preclinical Data 74 Demonstrates Significant 74 Initiates Clinical 74 Novel Oral 74 RNAi Therapeutics 73 Preclinical Data 73 Submits NDA 73 Tumor Targeting 73 Announces FDA Clearance 73 Phase III Clinical Trial 73 Initiates Clinical Trials 73 Develop Novel 73 Issued Patent 73 Initiates Phase II 73 IND Application 73 Completes Dosing 73 Presents Positive 73 Phase 2a Trial 73 Receives FDA Clearance 73 Significantly Improves 73 Study Evaluating 73 Improves Survival 72 Investigational Compound 72 Generic Version 72 Monoclonal Antibody 72 Milestone Payment 72 Patient Enrollment 72 Patients Treated With 72 Granted Orphan Drug 72 Collaborators Present 72 Anti Tumor 72 Files Patent Application 72 FDA Accepts 72 Receives Approvable Letter 72 Mylan Receives Approval 72 Study Demonstrates 72 GRAS Status 72 Announces Issuance 72 Anti Tumor Activity 72 Phase 2b Clinical Trial 72 Phase III Trial 72 JAK Inhibitor 71 Phase IIb Clinical Trial 71 Expanded Indication 71 FDA Approvals 71 Phase IIb Trial 71 Initiates Phase III 71 Data Suggest 71 Recombinant Human 71 Prolongs Survival 71 Orally Active 71 Orphan Status 71 Earns Milestone Payment 71 Cholesterol Lowering Drug 71 Obtains Exclusive License 71 Immunomedics Announces 71 Initiates Dosing 71 Collaborators Publish 71 Announces Initiation 71 Pivotal Phase III 71 RNAi Therapeutic 71 Initiates Enrollment 71 Demonstrates Potential 71 Psoriasis Drug 71 Well Tolerated 71 Receives Fast Track 70 Phase 2b Trial 70 Demonstrates Positive 70 Teva Provides Update 70 DOR BioPharma Announces 70 Enrolls First 70 Epilepsy Drug 70 Sign Licensing Agreement 70 BioSante Pharmaceuticals Announces 70 FDA Okays 70 Vaccine Adjuvant 70 Announce License Agreement 70 Pivotal Study 70 Lupus Drug 70 Osteoporosis Drug 70 Drug Shows Promise 70 Shows Promise 70 Kinase Inhibitor 70 Significantly Reduces 70 First Patient Dosed 70 Lung Cancer Drug 70 Topical Treatment 70 Begin Clinical Trials 70 Protease Inhibitor 70 Reports Preclinical Data 70 Rheumatoid Arthritis Drug 70 Shows Promising 70 Low Dose 70 Trial Evaluating 70 Milestone Payments 70 Adjuvant Treatment 70 Tyrosine Kinase Inhibitor 70 Presents Preclinical 70 Arthritis Drug 70 Positive Opinion 69 Gout Drug 69 Commercialize 69 Single Dose 69 Submits IND 69 Novel Antibiotic 69 Induces 69 Submits Application 69 Licenses Novel 69 FDA Approves 69 Vaccine Candidate 69 Awarded Qualifying Therapeutic 69 Generic Versions 69 NDA Submission 69 Oral Calcitonin 69 Schizophrenia Drug 69 Achieves Primary Endpoint 69 Immune Responses 69 Patient Enrolment 69 Investigational Treatment 69 Clinical Trial Evaluating 69 Successfully Completes Phase 69 Previously Treated 69 Awarded Patent 69 Receptor Agonist 69 Novel Compound 69 Hypertensive Patients 69 Initiates Phase 69 Taro Receives 69 Antitumor Activity 69 Drug Fails 69 Gets FDA Clearance 69 Combination Treatment 69 Efficacy Trial 69 IND Filing 69 FDA Orphan Drug 69 Improve Survival 69 Cocaine Addiction 69 Receives Marketing Authorization 68 Migraine Drug 68 FDA Approval 68 Pivotal Phase 68 Treating Chronic 68 Receives Notice 68 Commence Phase 68 Aptamer 68 Therapeutic Potential 68 Prostate Cancer Vaccine 68 Phase 2a Clinical Trial 68 Therapeutic Competitors Companies 68 Advanced Melanoma 68 Patents Issued 68 Submits Biologics License Application 68 Clinical Outcome 68 Blood Pressure Drug 68 Proves Effective 68 Initiate Clinical Trial 68 Demonstrates Efficacy 68 AnaSpec Introduces 68 Announces Tentative Approval 68 Chronic Hepatitis B 68 Scientists Identify 68 Commences Phase 68 Announces Publication 68 Reacquires 68 Severe Sepsis 68 Replacement Therapy 68 Combination REOLYSIN R 68 Malaria Vaccine 68 JAK2 Inhibitor 68 Reduces Risk 68 Molecular Diagnostic Test 68 Treatment Reduces 68 Researchers Identify 68 Obtains License 68 Receive Milestone Payment 68 Begins Shipment 68 Novel Therapeutic 68 Survival Benefit 68 Announces Poster Presentations 68 Effectively Treats 68 Combination Therapy 68 Miraculins Announces 68 Researchers Develop 68 Drug Resistant 68 Regenerative Cells 68 Phase IIa Clinical Trial 68 siRNA Delivery 68 Stem Cell Treatment 68 Orphan Drug Status 68 Novel Mechanism 68 Shows Promise Against 68 Orphan Designation 68 Inhibits 68 Antitumor 68 Advanced Colorectal Cancer 68 VIVUS Announces 68 Mouse Model 68 Seasonal Influenza Vaccine 68 Clinical Efficacy 68 Significantly Improved 68 Hsp# Inhibitor 68 Patients Enrolled 67 Preclinical Study 67 Submits Supplemental 67 Lorus Therapeutics Announces 67 Prophylactic Treatment 67 PRN FDA Approves 67 Receives Notification 67 Nicotine Vaccine 67 CysDisplay R 67 Patent Upheld 67 Testosterone Gel 67 Complicated Skin 67 Uses Thereof 67 Pooled Analysis 67 Improves Outcomes 67 Phase 1b Clinical Trial 67 Expand Collaboration 67 Anti Inflammatory 67 Vascular Inflammation 67 Fungal Infections 67 Attenuates 67 Long Term Efficacy 67 Receives Complete Response 67 Receives Positive Opinion 67 Hematological Cancers 67 Breast Cancer Recurrence 67 Demonstrates Ability 67 Announces License Agreement 67 Genes Involved 67 Demonstrates Potent 67 Receives CE Marking 67 Patent Lawsuit 67 Oral Interferon 67 Oral Fingolimod 67 Tumor Growth 67 FDA APPROVES 67 Abstract Accepted 67 Supplemental Biologics License Application 67 Novel Inhibitor 67 Announce Collaboration Agreement 67 Gene Variant 67 Asthma Treatment 67 Shows Efficacy 67 Submits Response 67 Disease Progression 67 Presents Positive Preclinical 67 Vitro Activity 67 Antisense Oligonucleotides 67 First Patient Enrolled 67 Receives SFDA Approval 67 Patent Dispute 67 Confirms Efficacy 67 Humanized Anti 67 Pivotal Trial 67 Bazedoxifene 67 Lowers Risk 67 Study Indicates 67 Investigational Agent 67 Provides Update Regarding 67 Patent Infringement Litigation 67 Metabolic Disorder 67 Files Provisional 67 Demonstrates Statistically Significant 67 Proven Effective 67 Monotherapy 67 Blood Clotting 67 Commercializes 67 Gene Mutation 67 Metastatic Melanoma 67 Chronic Hepatitis C 67 pralatrexate injection folate analogue 67 Begins Dosing 67 Biomarker Study 67 Oligonucleotides 67 Patients Treated 66 Transdermal Patch 66 Initiate Phase 66 Files Patent 66 Oral Mucositis 66 Metastatic Colorectal Cancer 66 Orphan Drug designations 66 Therapeutic Antibody 66 Clinical Trial Data 66 Smallpox Vaccine 66 Infected Patients 66 Treatment Naïve 66 Lanthanum Carbonate 66 Receives Favorable 66 Inhaled Insulin 66 Inhaled Corticosteroids 66 microRNA Therapeutics 66 Antibody Discovery 66 Epidermal Growth Factor Receptor 66 Atopic Dermatitis 66 First Patient Treated 66 Commences Phase III 66 Molecular Mechanism 66 Recombinant Protein 66 Adjuvant Therapy 66 Study Showed 66 Achieves Milestone 66 Holds Promise 66 Announces Presentation 66 Lung Cancer Trial 66 Autoimmune Diseases 66 Million Milestone Payment 66 Preclinical Efficacy 66 Launches Generic Version 66 Rotavirus Vaccine 66 Pafuramidine 66 Dramatically Increases 66 Tezampanel 66 Protein Biomarkers 66 Receptor Antagonist 66 Anticancer Drug 66 Identifies Potential 66 Scientists Develop 66 Sustained Release 66 Interferon Gamma 66 Initiate Phase III 66 Anticancer Activity 66 Patent Infringement Lawsuit 66 Interferon Beta 66 Interferon Alpha 66 Develops Novel 66 Anticancer Compound 66 Flamel Technologies Announces 66 Conjugate 66 Xcytrin R 66 Wound Dressing 66 NeutroPhase TM 66 Carboplatin Paclitaxel 66 Phase III Trials 66 Antiviral Drugs 66 Pediatric Patients 66 Protein Synthesis 66 Investigational Drug 66 Myelodysplastic Syndromes 66 Factor Xa Inhibitor 66 Methylnaltrexone 66 Granulocyte Colony Stimulating Factor 66 Virus Infection 66 Spectrum Pharmaceuticals Announces 66 Significantly Increases 66 Osteoporosis Treatment 66 Pharmacokinetic Study 66 Hepatitis B Vaccine 66 Overactive Bladder 66 II Clinical Trial 66 Novel Compounds 66 Cancer Cells 66 Statistically Significant 66 Novel Treatments 66 Announces Successful Completion 66 Acquires Exclusive 66 Smooth Muscle 66 Chemotherapeutic Agents 66 Aztreonam Lysine 66 Progenitor Cells 66 HuCAL GOLD R 66 Regulatory Clearance 66 Therapeutic Vaccine 66 Controlled Trial 65 Clinical Study Shows 65 Novel Vaccine 65 DNA Methylation 65 Fast Track Designation 65 Showed Significant 65 Endovascular Treatment 65 Blood Thinner 65 Cancer Treatments 65 Unfractionated Heparin 65 Receives Regulatory 65 Demonstrates Sustained 65 Synthetic Peptide 65 Diagnostic Tests 65 Successfully Treated 65 Avian Flu Vaccine 65 Beta Blocker 65 Obtains Patent 65 Emerging Therapies 65 Files Investigational 65 BioElectronics Announces 65 Aliskiren 65 Therapeutic Efficacy 65 entitled Compositions 65 Receives Tentative Approval 65 Cypher Sirolimus 65 Elderly Patients 65 Generic Version Of 65 k Clearance 65 Announces Positive 65 Chemokine Receptor 65 Ebola Vaccine 65 Significantly Reduced 65 Dose Ranging Study 65 Intellectual Property Portfolio 65 Renal Cell Carcinoma 65 Postmenopausal Women 65 Sign License Agreement 65 DARA logo 65 Immune Cell 65 Aloxi ® 65 Initiates Phase 2b 65 Appears Safe 65 R lenalidomide 65 Patent Infringement Lawsuit Against 65 TRANSDUR ™ 65 Announce Initiation 65 Advanced Prostate Cancer 65 Immunotherapeutic 65 Relapsing Multiple Sclerosis 65 Non Invasive 65 Achieves Significant 65 Anti Inflammatory Drug 65 Glatiramer Acetate 65 Conjugates 65 Mesothelioma Treatment 65 Kidney Function 65 Aurora Kinase 65 Safinamide 65 Further Validates 65 Double Blind Placebo 65 Improved Survival 65 Prodrug 65 Cholesterol Drug 65 Study Shows Benefits 65 Reports Positive 65 Oral Insulin 65 Patients Suffering 65 Cell Proliferation 65 Flagship Product 65 Kinase Inhibitors 65 Shows Statistically Significant 65 AVANIR Pharmaceuticals Announces 65 Milestone Payment From 65 Regulatory Approvals 65 Gene Linked 65 Rheumatoid Arthritis Patients 65 Ecallantide 65 Dendritic Cells 65 lead molecular radiotherapeutic 65 Mg Usa 65 Patent Infringement Case 65 Immune Cells 65 Beneficial Effects 65 Antibody Drug Conjugate 65 Commercially Available 65 Benign Prostatic Hyperplasia 65 PDUFA Date 65 Protein Involved 65 Soft Tissue Sarcoma 65 Randomized Clinical Trials 65 Signaling Pathway 65 Subgroup Analysis 65 Autologous Stem Cell Transplantation 65 Non Invasive Treatment 65 oligonucleotides Manoharan 65 Orphan Drug designation 65 Brain Metastases 65 Study Shows Significant 65 Reduced Risk 65 Tumor Cells 65 Predict Risk 65 Isavuconazole 65 Prostate Cancer Treatment 65 Valortim TM 65 Pulmonary Arterial Hypertension 65 platform HDL Mimetic 65 Analogs 65 Drug Combo 65 Slow Progression 65 KL4 Surfactant 65 C1 Inhibitor 65 Completes Patient Enrolment 65 Controlled Clinical Trial 65 Multiple Myeloma Patients 65 Desvenlafaxine Succinate 65 Resistant Hypertension 65 Ranolazine 65 Inc Therapeutic Competitors 65 Advanced Renal Cell 65 Settle Patent Litigation 65 Accelerate Commercialization 65 Study Validates 65 Medoxomil 65 Reveals Positive 65 Recurrent Breast Cancer 65 Clinical Study 65 Receives Positive 65 Announce Receipt 65 Randomized Phase 65 Potent Antiviral Activity 65 Receives Approval 65 Treatment Experienced 65 Settles Litigation 65 Derma Sciences Announces 64 Receives NASDAQ 64 Vaccine Adjuvants 64 Testosterone Patch 64 Treatment Regimen 64 Combo Therapy 64 Is Well Tolerated 64 HDAC Inhibitor 64 Successfully Treats 64 Regains NASDAQ 64 FDA Panel Recommends 64 Autoimmune Disease 64 Reveals Significant 64 Dry Powder Inhalers 64 Dry Powder Inhaler 64 Test Detects 64 Study Identifies 64 Therapeutic Competitors Report 64 Respiratory Virus 64 Cancer Vaccine 64 Controlled Study 64 Pharmaceuticals Initiates 64 rxRNA 64 Helps Predict 64 Anti Angiogenic 64 Mimetics 64 Cervical Cancer Vaccine 64 Previously Untreated 64 Anemia Drug 64 Technological Advances 64 Antigen Specific 64 Impairs 64 Prospective Randomized 64 Misonix Announces 64 Immune Mediated 64 Newly Identified 64 Allergic Rhinitis 64 Study Confirms 64 Regains Full 64 Bosutinib 64 Minimally Invasive Treatment 64 Commercialize Novel 64 Sangamo BioSciences Announces 64 Transdermal Drug 64 Hypercholesterolemia 64 Hip Prosthesis 64 Announce Commencement 64 Announces Licensing Agreement 64 ORLive Presents 64 Neuroprotection 64 Ovarian Cancer Treatment 64 Awarded Patents 64 Maribavir 64 Announce Merger Agreement 64 Immunostimulatory 64 Announce Licensing Agreement 64 Pivotal Clinical Trial 64 Therapy Improves 64 Liposomal 64 Data Indicate 64 Breast Cancer Cells 64 SFDA Approval 64 Intravenous Formulation 64 Suppresses 64 Obtains Approval 64 Diabetic Neuropathy 64 Hepatitis C Virus 64 Anti CD# Antibody 64 Announces Dosing 64 Patent Validity 64 Demonstrates Improved 64 Adjunctive Therapy 64 Cholesterol Lowering 64 Drug Eluting Stent 64 TB Vaccine 64 Randomized Double Blind 64 Being Studied 64 Radiation Induced 64 Hospital Acquired Pneumonia 64 Gastric Cancer 64 Meta Analysis 64 SABER ™ 64 Human Monoclonal Antibodies 64 Confirms Validity 64 Personalized Immunotherapy 64 Plaque Psoriasis 64 Nilotinib 64 Subsidiary Enters 64 Announcement acc 64 Prostate Cancer Patients 64 Fondaparinux 64 R bendamustine hydrochloride 64 Inflammatory Arthritis 64 Lung Cancer Survival 64 Confirmatory Phase 64 Combination Clinical Trial 64 Increases Risk 64 Announces Dismissal 64 Bird Flu Vaccine 64 Node Positive 64 Exercises Option 64 Protein Linked 64 Mutually Agree 64 Randomized Study 64 Demonstrated Significant 64 Announce Collaboration 64 Potentially Fatal 64 FDA Warns Against 64 Signaling Pathways 64 Disease Modifying 64 Diamyd Medical Diamyd 64 Cancer Vaccines 64 VYVANSE TM lisdexamfetamine 64 Tablet Formulation 64 Antiviral Activity 64 Marketing Authorisation 64 Angiogenic 64 ENLIGHT 64 Board Authorizes 64 Contrast Agent 64 ARRY # 64 Parathyroid Hormone 64 Randomized Clinical Trial 64 RegeneRx Receives 64 Monoclonal Antibodies 64 FOLOTYN ® 64 Cholesterol Drugs 64 Efficacious 64 ORADUR ® 64 Transdermal Delivery 64 Oral Spray 64 Gene Variants 64 Epilepsy Drugs 64 Licenses Patents 64 Signs Option Agreement 64 Cardiac Function 64 Genetic Disorder 64 Therapeutic Antibodies 64 Phase III Clinical Trials 63 Immunogenicity 63 Pending Acquisition 63 Diabetic Patients 63 Hepatic Encephalopathy 63 Genes Linked 63 Hepatocellular Carcinoma 63 Improve Outcomes 63 Strengthens Balance Sheet 63 NMDA Receptor 63 Provides Updates 63 Chemotherapy Regimen 63 Receives Clearance 63 Anthrax Vaccine 63 Embryonic Stem Cells 63 Vitrasert R 63 Invasive Fungal Infections 63 vapreotide acetate 63 Successful Completion 63 Modulates 63 Receives Tentative FDA 63 Treated Patients 63 SBIR Grant 63 IIa Clinical Trial 63 Mg Uk 63 TRANSDUR ® 63 Approvable 63 Treatment Resistant 63 Hepatitis C Virus HCV 63 Multicenter Trial 63 ELADUR TM 63 HCV Protease Inhibitor 63 Novel Method 63 Mouse Models 63 Antidepressant Drug 63 Genetic Variant 63 Nasdaq VNDA 63 Nitazoxanide 63 Fewer Side Effects 63 Gene Variation 63 NICE Recommends 63 Neural Stem Cells 63 Levels Linked 63 Help Predict 63 Preclinical Models 63 Protein Expression 63 Licensing Deal 63 Patent Application 63 Adenoma 63 Tigecycline 63 Obtains FDA 63 Clarifies Status 63 Adjuvant Chemotherapy 63 Circulating Tumor Cells 63 Immunomodulatory 63 Widely Used 63 Stent Restenosis 63 Genetic Mutation 63 Osteoarthritis Patients 63 Grants Orphan Drug 63 Phase 2b Study 63 Randomized Trials 63 Successfully Tested 63 Immune Therapy 63 Extended Release 63 Placebo Controlled Trial 63 Brain Cells 63 Nanoemulsion 63 Diabetic Nephropathy 63 Enters Into Collaboration 63 Advanced Pancreatic Cancer 63 HuCAL PLATINUM R 63 MEK Inhibitor 63 Gene Expression Analysis 63 Poniard Pharmaceuticals Announces 63 Patent Filing 63 Breast Tumors 63 product platforms AZX# 63 Announces Favorable 63 Imaging Technique 63 AVI BioPharma Announces 63 Vaccine Protects Against 63 Cell Adhesion 63 Thrombin topical Recombinant 63 Anticancer Drugs 63 STERIS Corporation Announces 63 Enlarged Prostate 63 Osteoporosis Drugs 63 Oligonucleotide 63 Novel Small Molecule 63 Eluting Stent 63 Civacir 63 Dose Escalation 63 Clinical Evaluation 63 Therapeutic Targets 63 Metabolic Disease 63 SPRYCEL ® 63 Genetic Tests 63 Novel Protein 63 Factor Receptor 63 Obtains Exclusive 63 Stent Implantation 63 NASDAQ Delisting Notice 63 Inflammatory Disease 63 Scientists Uncover 63 Regulatory Approval 63 Anti Clotting Drug 63 Prove Effective 63 Cancer Therapies 63 Diabetic Ulcers 63 Targeted Therapies 63 VentiRx Pharmaceuticals 63 Genotyping Test 63 Regains Compliance 63 Successfully Completed 63 Multicenter Randomized 63 PDL BioPharma Announces 63 Recommends Approval 63 Endothelial Cells 63 Universal Flu Vaccine 63 Resubmission 63 Biocompatibility 63 Hematological Malignancies 63 Long Term Survival 63 Extends Collaboration 63 Secures Financing 63 Effective Treatments 63 Pivotal Trials 63 FDA Approves Drug 63 Cardiovascular Events 63 CHMP Opinion 63 Progenitor Cell 63 Proves Successful 63 Reduces Pain 63 Diet Pill 63 Antithrombin 63 HIV Integrase 63 Patented Technology 63 Effective Than 63 Receives CE 63 Receives Favorable Ruling 63 Enrolling Patients 63 Poster Presentations 63 investigational humanized monoclonal antibody 63 Nuvelo Announces 63 Drug Coated Stent 63 Pharmacyclics Announces 63 Elevated Levels 63 Ridaforolimus 63 Dose Finding 63 GATTEX TM 63 Nasdaq SMTS develops manufactures 63 Subtypes 63 IMiDs ® 63 Darbepoetin Alfa 63 Dose Response 63 Pandemic Influenza Vaccine 63 Anti Angiogenesis 63 Rotavirus Vaccines 63 Correlation Between 63 Successfully Concludes 63 Secures Patent 63 Study Proves 63 Kidney Transplant Patients 63 Antisense Drug 63 Genetic Variations 63 Significant Improvements 63 Hormone Refractory Prostate Cancer 63 Phase 2a Study 62 Patients Receiving 62 Lubiprostone 62 Friedreich Ataxia FRDA 62 Clinical Trial 62 Voluntarily Withdraws 62 Patent Ruling 62 Patent Lawsuit Against 62 Patients Undergoing 62 Study Casts Doubt 62 Metastatic Prostate Cancer 62 Liver Toxicity 62 Bucindolol 62 Protease Inhibitors 62 Nasdaq Listing Requirements 62 Anticancer Agent 62 Shoulder Prosthesis 62 motexafin gadolinium Injection 62 PROSTASCINT R 62 Hip Implants 62 Study Sheds Light 62 Slows Progression 62 Marketing Authorization 62 Less Invasive 62 Unresectable 62 PDE# 62 Weight Loss Drug 62 Oncolytic 62 Discontinues 62 Orphan Drug status 62 Antifungal 62 Receives Commitment 62 Hepatitis C Treatment 62 Patient Treated 62 Fixed Dose Combination 62 Files Patent Infringement 62 Cancer Stem Cells 62 Signs Licensing Agreement 62 Patent Infringement Suit 62 Nasdaq XTLB 62 visit http:/www.mannkindcorp.com 62 Announce Settlement 62 Antiviral Therapy 62 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 62 Companion Diagnostic 62 CNS Disorders 62 Disease IBD 62 Renal Cancer 62 ABLYNX 62 Sapacitabine 62 Calcitonin 62 Generic Protonix 62 See CLINICAL PHARMACOLOGY 62 Cytotoxicity 62 Receives Approvals 62 Antigens 62 Therapy Evaluation 62 Jumps Higher 62 Completes Tender Offer 62 Detection Device 62 Unsolicited Tender Offer 62 Polymerase Inhibitor 62 Neulasta R 62 Erectile Dysfunction Drug 62 Novel Peptide 62 Contrast Agents 62 Faropenem 62 Report Analyzes 62 Randomized Controlled Trials 62 Receives Unsolicited 62 Doripenem 62 Nano Scale 62 Jointly Announce 62 Fentanyl Patch 62 Inflammatory Markers 62 Schizophrenia Treatment 62 Metformin HCl 62 Nanophase Announces 62 Magnetic Nanoparticles 62 Gastrointestinal Disorders 62 Zorbtive TM 62 Antiangiogenic 62 Patent Issuance 62 Underwritten Public 62 Japanese Encephalitis Vaccine 62 Therapeutic Competitors companiesandmarkets.com adEgemonye 62 Antiplatelet 62 Shingles Vaccine 62 Bevacizumab 62 Stakeholder Opinions 62 R Saizen R 62 novel emulsion formulation 62 Newly Diagnosed Multiple Myeloma 62 Acute Attacks 62 Nasdaq Delisting Notice 62 Atypical Antipsychotic 62 ELADUR ™ 62 Reperfusion Injury 62 Reductase 62 RECOTHROM R 62 Product Designation 62 Develop Innovative 62 TO AVOID PREGNANCY WHILE 62 Strongly Linked 62 Coronary Arteries 62 methylnaltrexone bromide 62 Increased Risk 62 Naturally Occurring 62 Bone Metastases 62 Fracture Risk 62 Tesamorelin 62 Haemophilus b Conjugate 62 Oracea TM 62 Commonly Used 62 TriCo Bancshares Announces 62 Detect Cancer 62 Lung Cancer Patients 62 Anthrax Toxin 62 Markets Examine 62 WorldHeart Announces 62 Hormone Therapy 62 Sevelamer 62 Inhaled Liposomal Ciprofloxacin 62 Announce Licensing 62 Vicriviroc 62 Integrase Inhibitor 62 Signs License Agreement 62 Gentium Announces 62 Aggressive Prostate Cancer 62 Respiratory Distress 62 Accelrys Announces 62 Microspheres 62 Adipose Derived Stem Cells 62 Nasdaq HALO 62 Tumor Targeted 62 Oral Fluid 62 Prospective Multicenter 62 acetonide FA 62 Topline Results 62 Nasdaq Deficiency Notice 62 Antimicrobial Coating 62 Sagent Pharmaceuticals Announces 62 Enters Into Agreement 62 Bafetinib 62 NASDAQ Listing Requirements 62 Abdominal Fat 62 Enters Agreement 62 Prolongs Life 62 product candidate Lpathomab 62 Leukemia Cells 62 Desvenlafaxine 62 Extracellular Matrix 62 Tuberculosis Vaccine 62 ALN HPN 62 ANDA Filing 62 Issues Guidance 62 Cardiovascular Outcomes 62 Patent Filings 62 Romidepsin 62 Oxidative Stress 62 FDA Warns 62 Receives Conditional 62 Taglich Brothers Initiates Coverage 62 Licensing Agreements 62 Androgen Deprivation Therapy 62 Wins Patent Infringement 62 Intravascular 62 Autoimmune Disorders 62 Skeletal Muscle 62 Diabetic Foot Ulcer 62 Lyophilized 62 Drug Maker 62 Study Pinpoints 62 THERAPEUTICS 62 Successfully Completes